

## **Foundations to Practice: Pathophysiology of Cancer, Cancer Treatment Modalities, and the Immune System**

**Wednesday, January 3, 2024  
UPMC Hillman Cancer Center  
Remote Access via Microsoft TEAMS**

### Learning Objectives

The learner will be able to:

1. Identify the role of the Foundations to Practice Series in providing care to patients with cancer.
2. Recognize characteristics of malignant disease.
3. Describe the meaning of cancer disparity.
4. Explain the role of different treatment modalities in treating patients with cancer.
5. Recall the immune system's function in the development and treatment of cancer.
6. Identify goals of treatment for patients with cancer.
7. Recognize the role of clinical trials in treating patients with cancer.
8. Demonstrate learning has occurred by receiving at least an 85% on the final knowledge assessment.

### Contact Hours

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 7 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

The maximum number of hours awarded for this Continuing Nursing Education activity is 7 contact hours.

To receive 7 Contact Hours, the learner must sign in, attend the entire activity, complete the activity evaluation, and achieve  $\geq 85\%$  on the knowledge assessment. Attendance will be tracked throughout the day of the course.

Schedule

7:30 am	Virtual Registration and TEAMS Login	
8:00 am	Welcome and Introduction to Foundations to Practice Series	Amy DiMaggio, MSN, RN, OCN
8:10 am	Pathophysiology of Cancer	Brittini Prosdocimo, MSN, RN, BMTCN
9:05 am	The Immune System and Immunotherapy	Melissa Wilson, PA-C
9:40 am	Alternative, Complementary, and Integrative Modalities	Susan Steube, BSN, RN, OCN, MS-MCST
10:20 am	Break	
10:30 am	Cancer Disparities	Amy DiMaggio, MSN, RN, OCN
11:15 am	Stem Cell Transplant and CAR T-Cell Therapy	Brittini Prosdocimo, MSN, RN, BMTCN
11:50 am	Lunch	
12:30 pm	Chemotherapy, Hormonal Therapy, and Biotherapy	Shrina Duggal, PharmD, BCOP
1:25 pm	Goals of Treatment and Treating on Time	Ketura Miller, BSN, RN, OCN
1:55 pm	Break	
2:05 pm	Clinical Trials	Jennifer Ruth, BSN, RN, CCRP
2:40 pm	Radiation Therapy	Lindsey Russell, PA-C
3:15 pm	Surgery	Elizabeth Higinbotham, BSN, RN, OCN
3:50 pm	Course Review	Amy DiMaggio, MSN, RN, OCN
4:00 pm	Adjournment	

Faculty Listing

*Amy DiMaggio, MSN, RN, OCN  
Clinical Education Specialist  
UPMC Hillman Cancer Center*

*Shrina Duggal, PharmD, BCOP  
Clinical Oncology Pharmacy  
Program Manager  
UPMC Hillman Cancer Center*

*Elizabeth Higinbotham, BSN, RN,  
OCN  
Assistant Clinical Instructor  
UPMC Mercy School of Nursing*

*Ketura Miller, BSN, RN, OCN  
Nurse Navigator  
UPMC Hillman Cancer Center,  
Pinnacle*

*Brittini Prosdocimo, MSN, RN,  
BMTCN  
Advanced Clinical Education  
Specialist  
UPMC Hillman Cancer Center*

*Lindsey Russell, PA-C  
Physician Assistant, Senior  
UPMC Hillman Cancer Center*

*Jennifer Ruth, BSN, RN, CCRP  
Clinical Research Manager  
UPMC Hillman Cancer Center*

*Susan Steube, BSN, RN, OCN,  
MS-MCST  
Senior Professional Staff Nurse  
UPMC Hillman Cancer Center*

*Melissa Wilson, PA-C  
Physician Assistant, Senior  
UPMC Hillman Cancer Center*

Disclosure of Conflicts of Interest

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by patients.

The following information was provided: Amy DiMaggio, Elizabeth Higinbotham/, Ketura Miller, Brittini Prosdocimo, Lindsey Russell, Jennifer Ruth, Susan Steube, Melissa Wilson, and the planning committee for this activity did not have any relevant financial relationships with a commercial interest.

Shrina Duggal has disclosed the following conflicts: CE Speakers' Bureau for Incyte, Astellas, and Pfizer; Consultant for UpToDate.